Clare Devlin
YOU?
Author Swipe
View article: Middle‐Out Physiologically Based Pharmacokinetic Modeling to Support Pediatric Dosing Recommendation for Alectinib
Middle‐Out Physiologically Based Pharmacokinetic Modeling to Support Pediatric Dosing Recommendation for Alectinib Open
Adult patients with anaplastic lymphoma kinase positive (ALK+) advanced non–small‐cell lung cancer (NSCLC) are treated with 600 mg alectinib twice daily (BID) as first‐line treatment. ALK positive solid and central nervous system (CNS) tum…
View article: Efficacy and safety of entrectinib in children with extracranial solid or central nervous system (CNS) tumours harbouring NTRK or ROS1 fusions
Efficacy and safety of entrectinib in children with extracranial solid or central nervous system (CNS) tumours harbouring NTRK or ROS1 fusions Open
Integrated data from three trials confirm entrectinib induces rapid and durable responses in children with NTRK or ROS1 fusion-positive tumours. The increased duration of safety monitoring does not demonstrate new or cumulative toxicity. R…
View article: Incidence and Predictors of Acute Kidney Injury Following Advanced Ovarian Cancer Cytoreduction at a Tertiary UK Centre: An Exploratory Analysis and Insights from Explainable Artificial Intelligence
Incidence and Predictors of Acute Kidney Injury Following Advanced Ovarian Cancer Cytoreduction at a Tertiary UK Centre: An Exploratory Analysis and Insights from Explainable Artificial Intelligence Open
Background/Objectives: The incidence of acute kidney injury (AKI) following advanced epithelial ovarian cancer (EOC) surgery has not been extensively studied. This study aimed to investigate the incidence of AKI and identify preoperative a…
View article: Incidence and Predictors of Acute Kidney Injury Following Advanced Ovarian Cancer Cytoreduction at a Tertiary UK Centre: An Exploratory Analysis and Insights from Explainable Artificial Intelligence
Incidence and Predictors of Acute Kidney Injury Following Advanced Ovarian Cancer Cytoreduction at a Tertiary UK Centre: An Exploratory Analysis and Insights from Explainable Artificial Intelligence Open
Background/Objectives: The incidence of acute kidney injury (AKI) following advanced epithelial ovarian cancer (EOC) surgery has not been extensively studied. This study aimed to investigate the incidence of AKI and identify preoperative a…
View article: TRLS-12. EFFICACY AND SAFETY OF ENTRECTINIB IN CHILDREN WITH<i>NTRK</i> OR<i>ROS1</i> FUSION-POSITIVE (FP) PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS
TRLS-12. EFFICACY AND SAFETY OF ENTRECTINIB IN CHILDREN WITH<i>NTRK</i> OR<i>ROS1</i> FUSION-POSITIVE (FP) PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS Open
BACKGROUND Entrectinib (CNS-penetrant, TRK/ROS1 inhibitor) has shown efficacy and safety in children with NTRK/ROS1-fp CNS tumors. We present updated data from an integrated analysis of children with NTRK/ROS1-fp CNS tumors enrolled in thr…
View article: Cobimetinib in Pediatric and Young Adult Patients with Relapsed or Refractory Solid Tumors (iMATRIX-cobi): A Multicenter, Phase I/II Study
Cobimetinib in Pediatric and Young Adult Patients with Relapsed or Refractory Solid Tumors (iMATRIX-cobi): A Multicenter, Phase I/II Study Open
ClinicalTrials.gov NCT02639546, registered December 24, 2015.
View article: Entrectinib in children and young adults with solid or primary CNS tumors harboring <i>NTRK</i>, <i>ROS1</i>, or <i>ALK</i> aberrations (STARTRK-NG)
Entrectinib in children and young adults with solid or primary CNS tumors harboring <i>NTRK</i>, <i>ROS1</i>, or <i>ALK</i> aberrations (STARTRK-NG) Open
Background Entrectinib is a TRKA/B/C, ROS1, ALK tyrosine kinase inhibitor approved for the treatment of adults and children aged ≥12 years with NTRK fusion-positive solid tumors and adults with ROS1 fusion-positive non–small-cell lung canc…